Climb Bio Inc

10-Year Study

CLYM.US · Healthcare · US · Common Stock

Executive Summary: Climb Bio Inc has compounded at -20.5% annually over the last 10 years, with a maximum drawdown of 95.4% and an annualized volatility of 194.8%.

1Y CAGR
+796.3%
3Y CAGR
+46.0%
5Y CAGR
-20.5%
10Y CAGR
-20.5%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
95.4%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.22
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
0.55
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
115.5%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2025 · +122.2%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2022 · -64.9%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
40%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
202611.760.0-4.228.8————————120.5%
20255.6-23.7-15.99.8-11.95.112.959.3-9.92.0-7.8111.6122.2%
2024-5.26.60.4158.88.7-7.816.6-15.7-27.2-24.9-15.6-44.3-33.3%
2023-4.61.7-18.58.3-7.0-4.1-4.3-1.1-0.80.0-2.75.5-26.4%
2022-13.6-0.3-6.9-62.321.2-21.15.3-3.85.61.2-21.743.4-64.9%
2021————————-30.0-3.1-17.4-27.3-59.3%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 194.8%. The dominant macroeconomic risk driver is SHV.US, accounting for 73.5% of variance. Idiosyncratic stock-specific factors contribute 13.8%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2021-08-0110000
2021-09-016998.83223043986
2021-10-016780.848579213702
2021-11-015601.401323472168
2021-12-014071.623199688595
2022-01-013518.878941222265
2022-02-013507.201245620864
2022-03-013265.862203191904
2022-04-011230.050603347606
2022-05-011490.8524717789023
2022-06-011175.5546905410665
2022-07-011237.8357337485404
2022-08-011191.124951342935
2022-09-011257.2985597508757
2022-10-011272.8688205527442
2022-11-01996.4966913195796
2022-12-011428.5714285714284
2023-01-011362.3978201634875
2023-02-011385.7532113662903
2023-03-011128.843908135461
2023-04-011222.265472946672
2023-05-011136.6290385363955
2023-06-011089.91825613079
2023-07-011043.2074737251849
2023-08-011031.5297781237834
2023-09-011023.7446477228493
2023-10-011023.7446477228493
2023-11-01996.4966913195796
2023-12-011050.9926041261192
2024-01-01996.4966913195796
2024-02-011062.6702997275204
2024-03-011066.5628649279877
2024-04-012759.828727131179
2024-05-013001.16776956014
2024-06-012767.6138575321133
2024-07-013226.9365511872315
2024-08-012720.9030751265086
2024-09-011981.3156870377577
2024-10-011488.9061891786687
2024-11-011257.2985597508757
2024-12-01700.6617360840794
2025-01-01739.5873880887505
2025-02-01564.4219540677306
2025-03-01474.8929544569871
2025-04-01521.6037368625924
2025-05-01459.3226936551187
2025-06-01482.6780848579213
2025-07-01544.959128065395
2025-08-01868.042039704165
2025-09-01782.4056052938886
2025-10-01797.9758660957569
2025-11-01735.6948228882833
2025-12-011557.026080186843
2026-01-011739.976644608797
2026-02-012783.1841183339825
2026-03-012666.407162319969
2026-04-013433.242506811989
Annual Return Matrix
YearAnnual Return
2022-0.6491395793499044
2023-0.2643051771117165
2024-0.33333333333333337
20251.2222222222222223
20261.205
Total Factor Risk
1.94768206316567
VTI.US Exposure
0.0023102862294107967
VEA.US Exposure
-0.0000795908720508949
VWO.US Exposure
0.0027495337377322114
QQQ.US Exposure
0.0003280306818705136
VTV.US Exposure
-0.0027687338695222
IJR.US Exposure
0.017624632280484463
QUAL.US Exposure
0.009109367209997391
SHV.US Exposure
0.7351357819882581
TLT.US Exposure
0.005853782028758029
LQD.US Exposure
0.03099134629798321
HYG.US Exposure
-0.00019562607380750157
GLD.US Exposure
0.009111405218347829
USO.US Exposure
0.0004871858468932791
VNQ.US Exposure
0.0035916357454303396
BTC-USD.CC Exposure
0.00045550816219070816
CPER.US Exposure
-0.0036734663391600917
VIX.INDX Exposure
0.014576816344432537
UUP.US Exposure
0.02337659815799912
TIP.US Exposure
0.012659819721068784
Idiosyncratic Exposure
0.1383556875036834
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
194.8%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$447.3M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+30.0%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+148.4%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
0.3% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
-0.20
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Climb Bio Inc a high-risk investment?

Climb Bio Inc (CLYM.US) has an annualized volatility of 194.8% and experienced a maximum drawdown of 95.4% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of CLYM.US?

Over the past 10 years, CLYM.US has generated a Compound Annual Growth Rate (CAGR) of -20.5%. It has had a positive return in 40% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Climb Bio Inc

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest